Ascendis Pharma A/S : 2020 Oncology R&D Day Presentation

Ascendis Pharma A/S

Virtual Oncology R&D Day

November 20, 2020

1

Cautionary Note On Forward-Looking Statements

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding our future results of operations and financial position, including our business strategy, prospective products, availability of funding, clinical trial results, product approvals and regulatory pathways, collaborations, licensing or other arrangements, the scope, progress, results and costs of developing our product candidates or any other future product candidates, the potential market size and size of the potential patient populations for our product candidates, timing and likelihood of success, plans and objectives of management for future operations, the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, and future results of current and anticipated products, are forward-looking statements. These forward-looking statements are based on our current expectations and beliefs, as well as assumptions concerning future events. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties and other factors are more fully described in our reports filed with or submitted to the Securities and Exchange Commission, including, without limitation, our most recent Annual Report on Form 20-F filed with the SEC on April 3, 2020 particularly in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.

Any forward-looking statement made by us in this presentation speaks only as of the date of this presentation and represents our estimates and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these statements publicly, whether as a result of new information, future events, changed circumstances or otherwise after the date of this presentation.

This presentation concerns product candidates that are or have been under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency or other foreign regulatory authorities. These product candidates are currently limited by U.S. Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.

Oncology product rights owned by Ascendis Pharma Oncology Division A/S (a wholly owned subsidiary of Ascendis Pharma A/S).

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. ©November 2020

2 Ascendis Pharma A/S.

All product candidates are investigational. For investor communication only. Not for use in promotion or product commercialisation.

Virtual Oncology R&D Day Agenda

9:00 a.m.

Welcome & Agenda Overview

Scott T. Smith, SVP, CFO

9:01-9:05 a.m.

Vision 3x3

Jan Møller Mikkelsen, President & CEO

9:05-9:20 a.m.

TransConTM Platform & Product Innovation

Kennett Sprogøe, Ph.D., SVP, Head of

Innovation and Research

9:20-10:00 a.m.

TransCon TLR7/8 Agonist & TransCon IL-2β/γ Juha Punnonen, M.D., Ph.D., SVP, Head of Oncology

Stina Singel, M.D., Ph.D., Head of Clinical

Development, Oncology

10:00-10:30 a.m.

Q&A

		All product candidates are investigational. For investor communication
3		only. Not for use in promotion or product commercialisation.

Vision 3x3

Jan Møller Mikkelsen

President & CEO

4